Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | PDE9A | O76083 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608325 | 0.95 | MTOR (0.47) | MTORADORA2AADORA1PRKCQPDE9A | |
| SCHEMBL12371670 | 0.95 | MTOR (0.47) | MTORADORA2AADORA1PRKCQPDE9A | |
| SCHEMBL13620400 | 0.89 | PRKCQ (0.46) | MTORADORA2AADORA1PRKCQCYP3A4 | |
| SCHEMBL12371750 | 0.88 | RIPK2 (0.42) | PRKCQCYP3A4CYP2C9 | |
| SCHEMBL12371700 | 0.86 | CYP2C9 (0.54) | ADORA2AADORA1PRKCQPDE9AHTR6 | |
| SCHEMBL12400577 | 0.86 | CYP3A4 (0.41) | PRKCQCYP3A4CYP2C9 | |
| SCHEMBL12371692 | 0.86 | PRKCQ (0.41) | PRKCQCYP3A4CYP2C9 | |
| SCHEMBL12371611 | 0.85 | BRD4 (0.39) | MTORADORA2AADORA1PRKCQ | |
| SCHEMBL12371687 | 0.84 | PRKCQ (0.44) | ADORA2APRKCQCYP3A4CYP2C9 | |
| SCHEMBL12371632 | 0.84 | PRKCQ (0.43) | MTORADORA2AADORA1PRKCQCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2008143674-A1 | PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | MTOR 534/4885ADORA2A 995/4885ADORA1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.